This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harris, L. N. Articles by Winer, E. P. Search for Related Content PubMed PubMed Citation Articles by Harris, L. N. Articles by Winer, E. P. Related Collections Commentary

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

Authors' Affiliations: ¹ Dana-Farber Cancer Institute; ² Beth Israel Deaconess Medical Center; ³ Biostatistics Department, Harvard School of Public Health; ⁴ Massachusetts General Hospital; ⁵ Brigham and Women's Hospital, Boston, Massachusetts and ⁶ Abbott Molecular, Des Plaines, Illinois

Requests for reprints: Lyndsay N. Harris, Department of Medical Oncology, Yale University Medical Center, 333 Cedar Street, New Haven, CT 06510. Phone: 203-785-3213; E-mail: Lyndsay.harris{at}yale.edu.

Purpose: To assess pathologic complete response (pCR), clinical response, feasibility, safety, and potential predictors of response to preoperative trastuzumab plus vinorelbine in patients with operable, human epidermal growth factor receptor 2 (HER2)–positive breast cancer.

Experimental Design: Forty-eight patients received preoperative trastuzumab and vinorelbine weekly for 12 weeks. Single and multigene biomarker studies were done in an attempt to identify predictors of response.

Results: Eight of 40 (20%) patients achieved pCR (95% confidence interval, 9-36%). Of 9 additional patients recruited for protocol-defined toxicity analysis, 8 were evaluable; 42 of 48 (88%) patients had clinical response (16 patients, clinical complete response; 26 patients, clinical partial response). T₁ tumors more frequently exhibited clinical complete response (P = 0.05) and showed a trend to exhibit pCR (P = 0.07). Five (13%) patients experienced grade 1 cardiac dysfunction during preoperative treatment. Neither HER2 nor estrogen receptor status changed significantly after exposure to trastuzumab and vinorelbine. RNA profiling identified three top-level clusters by unsupervised analysis. Tumors with extremes of response [pCR (n = 3) versus nonresponse (n = 3)] fell into separate groups by hierarchical clustering. No predictive genes were identified in pCR tumors. Nonresponding tumors were more likely to be T₄ stage (P = 0.02) and express basal markers (P < 0.00001), growth factors, and growth factor receptors. Insulin-like growth factor-I receptor membrane expression was associated with a lower response rate (50% versus 97%; P = 0.001).

Conclusions: Preoperative trastuzumab plus vinorelbine is active and well tolerated in patients with HER2-positive, operable, stage II/III breast cancer. HER2-overexpressing tumors with a basal-like phenotype, or with expression of insulin-like growth factor-I receptor and other proteins involved in growth factor pathways, are more likely to be resistant to this regimen.

Commentary

Will Single-Time Tumor Profiling and a "Guilt by Association" Approach Allow Us to Outsmart HER2-Positive Breast Cancer?

Carlos L. Arteaga
Clin. Cancer Res. 2007 13: 1071-1073. [Full Text] [PDF]

This article has been cited by other articles:

				J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]

				M. Narayan, J. A. Wilken, L. N. Harris, A. T. Baron, K. D. Kimbler, and N. J. Maihle Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells Cancer Res., March 15, 2009; 69(6): 2191 - 2194. [Abstract] [Full Text] [PDF]

				J. S. Parker, M. Mullins, M. C.U. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, X. He, Z. Hu, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes J. Clin. Oncol., March 10, 2009; 27(8): 1160 - 1167. [Abstract] [Full Text] [PDF]

				J. H. Law, G. Habibi, K. Hu, H. Masoudi, M. Y.C. Wang, A. L. Stratford, E. Park, J. M.W. Gee, P. Finlay, H. E. Jones, et al. Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival Cancer Res., December 15, 2008; 68(24): 10238 - 10246. [Abstract] [Full Text] [PDF]

				G. Somlo, P. Chu, P. Frankel, W. Ye, S. Groshen, J. H. Doroshow, K. Danenberg, and P. Danenberg Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome Ann. Onc., November 1, 2008; 19(11): 1853 - 1859. [Abstract] [Full Text] [PDF]

				S. E. Wang, B. Xiang, M. Guix, M. G. Olivares, J. Parker, C. H. Chung, A. Pandiella, and C. L. Arteaga Transforming Growth Factor {beta} Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab Mol. Cell. Biol., September 15, 2008; 28(18): 5605 - 5620. [Abstract] [Full Text] [PDF]

				X. Li, M. T. Lewis, J. Huang, C. Gutierrez, C. K. Osborne, M.-F. Wu, S. G. Hilsenbeck, A. Pavlick, X. Zhang, G. C. Chamness, et al. Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy J Natl Cancer Inst, May 7, 2008; 100(9): 672 - 679. [Abstract] [Full Text] [PDF]

				D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells Cancer Res., March 1, 2008; 68(5): 1471 - 1477. [Abstract] [Full Text] [PDF]

				A. K. Chakraborty, K. Liang, and M. P. DiGiovanna Co-Targeting Insulin-Like Growth Factor I Receptor and HER2: Dramatic Effects of HER2 Inhibitors on Nonoverexpressing Breast Cancer Cancer Res., March 1, 2008; 68(5): 1538 - 1545. [Abstract] [Full Text] [PDF]

				G. Alexe, G. S. Dalgin, D. Scanfeld, P. Tamayo, J. P. Mesirov, C. DeLisi, L. Harris, N. Barnard, M. Martel, A. J. Levine, et al. High Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast Cancers Correlates with Lower Recurrence Rates Cancer Res., November 15, 2007; 67(22): 10669 - 10676. [Abstract] [Full Text] [PDF]

				L. Harris, D. Toppmeyer, and B. G. Haffty In Reply J. Clin. Oncol., April 1, 2007; 25(10): 1295 - 1296. [Full Text] [PDF]

				C. L. Arteaga Will Single-Time Tumor Profiling and a "Guilt by Association" Approach Allow Us to Outsmart HER2-Positive Breast Cancer? Clin. Cancer Res., February 15, 2007; 13(4): 1071 - 1073. [Full Text] [PDF]